Ruane, Cunniff & Goldfarb L.P. Atai Life Sciences N.V. Call Options Transaction History
Ruane, Cunniff & Goldfarb L.P.
- $4.98 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ATAI
# of Institutions
111Shares Held
31.3MCall Options Held
494KPut Options Held
315K-
Ubs Group Ag7.7MShares$40.3 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.43MShares$28.4 Million0.02% of portfolio
-
Morgan Stanley New York, NY3.49MShares$18.3 Million0.0% of portfolio
-
Pale Fire Capital Se Prague, 2N2.64MShares$13.8 Million0.59% of portfolio
-
Black Rock Inc. New York, NY1.31MShares$6.84 Million0.0% of portfolio
About ATAI Life Sciences N.V.
- Ticker ATAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 165,875,008
- Market Cap $868M
- Description
- Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...